Literature DB >> 27909826

Profile and Determinants of Disability in Psychotic Disorders in Nigeria.

Victor Olufolahan Lasebikan1, Olatunde Ayinde2.   

Abstract

We compared profile and predictors of disability among 210 patients with schizophrenia, schizoaffective disorder, bipolar I disorder with psychosis and depression with psychosis, respectively in a Nigerian clinical population, using the WHO Disability Assessment Schedule, (2.0). Severity of psychosis was determined with Positive and Negative Symptoms Scale, functioning was assessed using the Global Assessment of Functioning Scale, medication adherence with the Medication Adherence Questionnaire. Analyses were by SPSS 20.0. There were remarkable differences in the predictors of disability across these psychotic disorders. The findings strengthens the significance of psychosocial rehabilitation in patients with psychosis as clinical remission and medication adherence did not equate functional recovery.

Entities:  

Keywords:  Bipolar Disorder; Community-rehabilitation; Depression; Disability; Schizoaffective disorder; Schizophrenia

Mesh:

Year:  2016        PMID: 27909826     DOI: 10.1007/s10597-016-0070-y

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  47 in total

Review 1.  Psychosocial rehabilitation and psychiatry in the treatment of schizophrenia--what are the boundaries?

Authors:  L L Bachrach
Journal:  Acta Psychiatr Scand Suppl       Date:  2000

Review 2.  The role of dopamine in the pathophysiology of depression.

Authors:  Boadie W Dunlop; Charles B Nemeroff
Journal:  Arch Gen Psychiatry       Date:  2007-03

Review 3.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.

Authors:  Michael F Green
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

4.  Predictors of long-term work disability in Major Depressive Disorder: a prospective study.

Authors:  H J Rytsälä; T K Melartin; U S Leskelä; T P Sokero; P S Lestelä-Mielonen; E T Isometsä
Journal:  Acta Psychiatr Scand       Date:  2007-03       Impact factor: 6.392

5.  A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.

Authors:  Mauricio Tohen; Joseph F Goldberg; Ana Maria Gonzalez-Pinto Arrillaga; Jean M Azorin; Eduard Vieta; Marie-Christine Hardy-Bayle; William B Lawson; Robin A Emsley; Fan Zhang; Robert W Baker; Richard C Risser; Madhav A Namjoshi; Angela R Evans; Alan Breier
Journal:  Arch Gen Psychiatry       Date:  2003-12

6.  The Australian National Survey of Psychotic Disorders: profile of psychosocial disability and its risk factors.

Authors:  O Gureje; H Herrman; C Harvey; V Morgan; A Jablensky
Journal:  Psychol Med       Date:  2002-05       Impact factor: 7.723

7.  The presentation of early-onset psychotic disorders.

Authors:  Jean Starling; Leanne M Williams; Cassandra Hainsworth; Anthony W Harris
Journal:  Aust N Z J Psychiatry       Date:  2012-10-09       Impact factor: 5.744

8.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Authors:  John M Kane; William H Carson; Anutosh R Saha; Robert D McQuade; Gary G Ingenito; Dan L Zimbroff; Mirza W Ali
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

Review 9.  A continuum of psychosis, one human gene, and not much else--the case for homogeneity.

Authors:  T J Crow
Journal:  Schizophr Res       Date:  1995-10       Impact factor: 4.939

10.  Neuropsychological and functional outcomes in recent-onset major depression, bipolar disorder and schizophrenia-spectrum disorders: a longitudinal cohort study.

Authors:  R S C Lee; D F Hermens; S L Naismith; J Lagopoulos; A Jones; J Scott; K M Chitty; D White; R Robillard; E M Scott; I B Hickie
Journal:  Transl Psychiatry       Date:  2015-04-28       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.